Ammirabile Angela, Cavinato Lara, Ferro Carola Anna Paolina, Fiz Francesco, Savino Matteo Stefano, Russolillo Nadia, Balbo Mussetto Annalisa, Ragaini Elisa Maria, Lanza Ezio, Akpinar Reha, Procopio Fabio, Francone Marco, Terracciano Luigi Maria, Gallo Teresa, De Rosa Giovanni, Ferrero Alessandro, Di Tommaso Luca, Ieva Francesca, Torzilli Guido, Viganò Luca
Department of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Diagnostic and Interventional Radiology, IRCCS Humanitas Research Hospital, Milan, Italy.
MOX Laboratory, Department of Mathematics, Politecnico di Milano, Milan, Italy.
Eur J Surg Oncol. 2025 Mar;51(3):109557. doi: 10.1016/j.ejso.2024.109557. Epub 2024 Dec 16.
The standard treatment of colorectal liver metastases (CRLM) is surgery with perioperative chemotherapy. A tumor response to systemic therapy confirmed at pathology examination is the strongest predictor of survival, but it cannot be adequately predicted in the preoperative setting. This bi-institutional retrospective study investigates whether CT-based radiomics of CRLM and peritumoral tissue provides a reliable non-invasive estimation of the pathological tumor response to chemotherapy.
All consecutive patients undergoing liver resection for CRLM at the two institutions were considered. Only patients with a radiological partial response or stable disease at chemotherapy and with a preoperative/post-chemotherapy CT performed <60 days before surgery were included. The pathological response was evaluated according to the tumor regression grade (TRG). The tumor (Tumor-VOI) was manually segmented on the portal phase of the CT and a 5-mm ring of peritumoral tissue was automatically generated (Margin-VOI). The predictive models underwent internal validation.
Overall, 222 patients were included; 64 had a pathological response (29 %, TRG1-3). Two-third of patients displaying a radiological response (111/170) did not have a pathological one (TRG4-5). For TRG1-3 prediction, the clinical model performed fairly (Accuracy = 0.725, validation-AUC = 0.717 95%CI = 0.652-0.788). Radiomics improved the results: the model combining the clinical data and Tumor-VOI features had Accuracy = 0.743 and validation-AUC = 0.729 (95%CI = 0.665-0.798); the full model (clinical/Tumor-VOI/Margin-VOI) achieved Accuracy = 0.820 and validation-AUC = 0.768 (95%CI = 0.707-0.826).
CT-based radiomics of CRLM allows an insightful non-invasive assessment of TRG. The combined analysis of the tumor and peritumoral tissue improves the prediction. In association with clinical data, the radiomic indices outperform standard radiological and clinical evaluation.
结直肠癌肝转移(CRLM)的标准治疗方法是手术联合围手术期化疗。病理检查证实的肿瘤对全身治疗的反应是生存的最强预测指标,但在术前无法充分预测。这项双机构回顾性研究调查了基于CT的CRLM和瘤周组织的放射组学是否能可靠地无创估计化疗的病理肿瘤反应。
纳入了在两家机构接受CRLM肝切除术的所有连续患者。仅纳入化疗后放射学部分缓解或病情稳定且术前/化疗后CT检查在手术前<60天进行的患者。根据肿瘤退缩分级(TRG)评估病理反应。在CT的门静脉期手动分割肿瘤(肿瘤感兴趣区),并自动生成5毫米的瘤周组织环(边缘感兴趣区)。对预测模型进行内部验证。
总共纳入222例患者;64例有病理反应(29%,TRG1-3)。三分之二显示放射学反应的患者(111/170)没有病理反应(TRG4-5)。对于TRG1-3预测,临床模型表现一般(准确率=0.725,验证AUC=0.717,95%CI=0.652-0.788)。放射组学改善了结果:结合临床数据和肿瘤感兴趣区特征的模型准确率=0.743,验证AUC=0.729(95%CI=0.665-0.798);完整模型(临床/肿瘤感兴趣区/边缘感兴趣区)的准确率=0.820,验证AUC=0.768(95%CI=0.707-0.826)。
基于CT的CRLM放射组学能够对TRG进行有见地的无创评估。肿瘤和瘤周组织的联合分析可改善预测。与临床数据相结合,放射组学指标优于标准放射学和临床评估。